Drugs / Merck Aluminum Phosphate Adjuvant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01986010 | Nov 2013 → Apr 2016 | cytomegalovirus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Merck Aluminum Phosphate Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01986010 ↗ |
| Known as | MAPA | “V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM” NCT01986010 ↗ |
| Route | Intramuscular | “V160 plus MAPA administered as a 0.75 mL intramuscular injection” NCT01986010 ↗ |